TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2872060

Group type: EXPERIMENTAL
Intervention: CM57755
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29570512

Group type: EXPERIMENTAL
Intervention: Effervescent paracetamol (1 g three times a day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Noneffervescent paracetamol
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Effervescent paracetamol
Number of subjects: 46
Study: 26868270

Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quitting smoking (7-day point prevalence)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quitting smoking (30-day point prevalence)
Number of subjects: 0
Study: 24903062

Group type: EXPERIMENTAL
Intervention: baby-CIMT
Number of subjects: 0

Group type: COMPARATOR
Intervention: baby-massage
Number of subjects: 0
Study: 22333738

Group type: EXPERIMENTAL
Intervention: Brief counselling session on alcohol risk reduction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health education leaflet
Number of subjects: 0
Study: 20466589

Group type: EXPERIMENTAL
Intervention: Pregabalin 50 mg/day
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Pregabalin 100 mg/day
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg/day
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Pregabalin 450 mg/day
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Pregabalin (various doses)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 18603250

Group type: EXPERIMENTAL
Intervention: Intrauterine instillation of 5 mL of 1% lignocaine 2 minutes prior to the procedure
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral naproxen 375 mg self-administered 1 hour prior to HSG
Number of subjects: 100
Study: 19204604

Group type: EXPERIMENTAL
Intervention: Supervised, mixed-type exercise program (20 sessions over 12 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group continued habitual activities
Number of subjects: 32
Study: 16160876

Group type: EXPERIMENTAL
Intervention: SR bupropion (300 mg/day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Free smoke
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: SR bupropion
Number of subjects: 23
Study: 11693589

Group type: EXPERIMENTAL
Intervention: Child training treatment group (CT) utilizing the Incredible Years Dinosaur Social Skills and Problem Solving Curriculum
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Child training treatment group (CT)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Waiting-list control group (CON)
Number of subjects: 99
Study: 9395155

Group type: EXPERIMENTAL
Intervention: Bech-Rafaelsen Mania Scale (MAS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Modified Bech-Rafaelsen Mania Scale (MAS-M)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MAS-M
Number of subjects: 100
Study: 8116059

Group type: EXPERIMENTAL
Intervention: High dose vitamin A
Number of subjects: 235

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 235
Study: 3553455

Group type: EXPERIMENTAL
Intervention: Antibiotics (cefazolin and gentamicin) administered in the immediate preoperative and intraoperative periods
Number of subjects: 846

Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: Antibiotics (cefazolin and gentamicin)
Number of subjects: 846
Study: 12068839

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 187
Study: 30160499

Group type: EXPERIMENTAL
Intervention: Low risk drinking during treatment
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Mostly abstinent during treatment
Number of subjects: 877

Group type: COMPARATOR
Intervention: Heavy drinking during treatment
Number of subjects: 877
Study: 27916914

Group type: EXPERIMENTAL
Intervention: Private sector service delivery (PSSD) of urine-diverting dry latrines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Government standard delivery (GSD) of cistern-flush toilets or ventilated improved pit latrines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Private sector service delivery (PSSD)
Number of subjects: 0
Study: 24906406

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy delivered by healthcare assistants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 22340549

Group type: EXPERIMENTAL
Intervention: Repeated transradial coronary intervention (r‐TRI)
Number of subjects: 423

Group type: COMPARATOR
Intervention: Initial transradial intervention (i‐TRI)
Number of subjects: 423
Study: 21287460

Group type: EXPERIMENTAL
Intervention: 0.5% nifedipine cream for 4 weeks
Number of subjects: 110

Group type: COMPARATOR
Intervention: Stool softeners and 2% lidocaine cream for 4 weeks
Number of subjects: 110
Study: 18387065

Group type: EXPERIMENTAL
Intervention: Cefoperazone-sulbactam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ceftazidime + Amikacin + Metronidazole (control)
Number of subjects: 0
Study: 15983523

Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acid (MUFA) diet
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saturated fatty acid (SFA) diet
Number of subjects: 15
Study: 12093304

Group type: EXPERIMENTAL
Intervention: Paclitaxel and cisplatin
Number of subjects: 231

Group type: COMPARATOR
Intervention: Cyclophosphamide and cisplatin
Number of subjects: 231
Study: 10710823

Group type: EXPERIMENTAL
Intervention: New Cyclosporine A microemulsion formulation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference market standard Cyclosporine A microemulsion
Number of subjects: 24
Study: 8964641

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 26
Study: 2117054

Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (GTN patches)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6992916

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 388

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 388
Study: 30836807

Group type: EXPERIMENTAL
Intervention: HBOT (20‐40 sessions) plus conventional treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 30
Study: 30113568

Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 205

Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 205
Study: 26931522

Group type: EXPERIMENTAL
Intervention: Tonsillectomy with uvulopalatopharyngoplasty (TE‐UPPP)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 42
Study: 24983742

Group type: EXPERIMENTAL
Intervention: Resveratrol plus carboxymethyl-β-glucan
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 22537541

Group type: EXPERIMENTAL
Intervention: Hypofractionation (62 Gy at 3.1 Gy per fraction in 5 weeks) + 9-month androgen deprivation therapy
Number of subjects: 168

Group type: COMPARATOR
Intervention: Conventional fractionation (80 Gy at 2 Gy per fraction in 8 weeks) + 9-month androgen deprivation therapy
Number of subjects: 168
Study: 20397271

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum
Number of subjects: 13
Study: 17999708

Group type: EXPERIMENTAL
Intervention: Haloperidol (1 mg)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Droperidol (0.625 mg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 150
Study: 16446682

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (5 g creatine monohydrate, 4 times daily for 6 days)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (flavored drink without creatine monohydrate)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 14630885

Group type: EXPERIMENTAL
Intervention: Breakfast meal
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Lunch meal
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Dinner meal
Number of subjects: 14
Study: 11081314

Group type: EXPERIMENTAL
Intervention: Aldactone (200 mg i.v.)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Furosemide (20 mg i.v.)
Number of subjects: 21
Study: 8671857

Group type: EXPERIMENTAL
Intervention: CsA + enalapril (20mg p.o. oad)
Number of subjects: 24

Group type: COMPARATOR
Intervention: CsA (7.5 mg/kg. b.i.d. in olive oil)
Number of subjects: 24
Study: 1315826

Group type: EXPERIMENTAL
Intervention: Low-sodium diet (10 mmol/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-sodium diet (800 mmol/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-sodium diet with added potassium (100 mmol/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline (free access to sodium)
Number of subjects: 0
Study: 4096205

Group type: EXPERIMENTAL
Intervention: 1% pilocarpine solution with nasolacrimal obstruction (NLO)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 1% pilocarpine solution with eyelid closure (EC)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 1% pilocarpine solution with both NLO and EC
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 1% pilocarpine solution with neither NLO nor EC
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 3% pilocarpine ointment
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 1% pilocarpine solution
Number of subjects: 6
Study: 30907209

Group type: EXPERIMENTAL
Intervention: 600 µg of misoprostol (oral or vaginal)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo (30 mg vitamin B6)
Number of subjects: 253
Study: 29233719

Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (60% carbohydrate, 20% fat)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Moderate-carbohydrate diet (40% carbohydrate, 40% fat)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (20% carbohydrate, 60% fat)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Ad libitum feeding phase following the test phase
Number of subjects: 164
Study: 26813359

Group type: EXPERIMENTAL
Intervention: PEGylated human recombinant hyaluronidase (PEGPH20) at doses of 1.0 μg/kg (n = 4), 1.6 μg/kg (n = 4), or 3.0 μg/kg (n = 20) in combination with gemcitabine (Gem)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: PEGPH20 in combination with Gem for patients with high hyaluronan (HA) levels
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: PEGPH20 in combination with Gem for patients with low hyaluronan (HA) levels
Number of subjects: 28
Study: 22723960

Group type: EXPERIMENTAL
Intervention: 4HR (isoniazid plus rifampicin for 4 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 6HE (isoniazid plus ethambutol for 6 months)
Number of subjects: 0
Study: 20147575

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 21
Study: 18541041

Group type: EXPERIMENTAL
Intervention: Craniosacral therapy (CST)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Low-strength static magnets (LSSM)
Number of subjects: 109
Study: 15747273

Group type: EXPERIMENTAL
Intervention: PCV-PEEP
Number of subjects: 25

Group type: COMPARATOR
Intervention: PCV-ZEEP
Number of subjects: 25

Group type: COMPARATOR
Intervention: VCV-ZEEP
Number of subjects: 25
Study: 12220774

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 352
Study: 9825371

Group type: EXPERIMENTAL
Intervention: i.v. propafenone (PFN) (2 mg/kg bolus followed by 0.0078 mg/kg/min infusion)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: o.s. propafenone (PFN) (600 mg)
Number of subjects: 123

Group type: COMPARATOR
Intervention: placebo (PLA)
Number of subjects: 123
Study: 8024919

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2681717

Group type: EXPERIMENTAL
Intervention: Sodium heparin
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Calcium heparin
Number of subjects: 75

Group type: COMPARATOR
Intervention: No heparin (anti-embolism stockings)
Number of subjects: 75
Study: 1090708

Group type: EXPERIMENTAL
Intervention: Major tranquilizer (neuroleptic) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Therapy resistant schizophrenic patients
Number of subjects: 0
Study: 29363217

Group type: EXPERIMENTAL
Intervention: Oxycodone 15 mg
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Imipramine 75 mg
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Clobazam 20 mg
Number of subjects: 149

Group type: COMPARATOR
Intervention: Active placebo tolterodine 1 mg
Number of subjects: 149
Study: 27509214

Group type: EXPERIMENTAL
Intervention: L-PRF socket filling
Number of subjects: 22

Group type: COMPARATOR
Intervention: Natural healing (Control)
Number of subjects: 22
Study: 25362008

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg/5 mL elemental zinc as zinc sulfate) for 2 weeks
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo (syrup base) for 2 weeks
Number of subjects: 272
Study: 22674156

Group type: EXPERIMENTAL
Intervention: Intravenous butorphanol (1 mg loading dose followed by 0.2 mg/h infusion)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Physiological saline (infusion of the same volume)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Intravenous butorphanol
Number of subjects: 91

Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 91
Study: 20299607

Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg/d
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study: 18064534

Group type: EXPERIMENTAL
Intervention: Autoimmune thyroid disease (ATD)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: MDS patients
Number of subjects: 101
Study: 15921927

Group type: EXPERIMENTAL
Intervention: Follow-up phone calls to black churches
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Follow-up phone calls to white churches
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group for black churches
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group for white churches
Number of subjects: 79
Study: 12675179

Group type: EXPERIMENTAL
Intervention: Vecuronium bromide (0.015 mg/kg) followed by repeat dose (0.08 mg/kg) at peak D1 suppression
Number of subjects: 22

Group type: COMPARATOR
Intervention: Vecuronium bromide (0.08 mg/kg) at peak DBS ratio suppression
Number of subjects: 22
Study: 10326708

Group type: EXPERIMENTAL
Intervention: Physical activity training (30 minutes daily biking on an ergometer in supine position)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 59
Study: 7843434

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cervical cap insemination
Number of subjects: 42
Study: 2636408

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 35

Group type: COMPARATOR
Intervention: Ketotifen and beclomethason diproprionate
Number of subjects: 35
Study: 366454

Group type: EXPERIMENTAL
Intervention: Tilorone hydrochloride, 1 gm per week
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7064013

Group type: EXPERIMENTAL
Intervention: Laminaria tents
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vaginal prostaglandin E2
Number of subjects: 20
Study: 31960395

Group type: EXPERIMENTAL
Intervention: Diet education program
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (guidance for swallowing exercise only)
Number of subjects: 84
Study: 30844848

Group type: EXPERIMENTAL
Intervention: Molecular allergy diagnostics (MAD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laboratory allergy diagnostics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Allergen immunotherapy
Number of subjects: 0
Study: 30111722

Group type: EXPERIMENTAL
Intervention: BLISS (Baby-Led Weaning, modified)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control (traditional spoon-feeding)
Number of subjects: 206
Study: 27899400

Group type: EXPERIMENTAL
Intervention: Sertraline (titrated up to a maximum of 100 mg daily over 28 days)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 25099071

Group type: EXPERIMENTAL
Intervention: Yogurt drink with added plant stanol esters (4 g)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Regular yogurt drink (Control)
Number of subjects: 40
Study: 20881023

Group type: EXPERIMENTAL
Intervention: Flu vaccination
Number of subjects: 5
Study: 19447438

Group type: EXPERIMENTAL
Intervention: Holmium laser ablation of the prostate
Number of subjects: 109

Group type: COMPARATOR
Intervention: Photoselective vaporization of the prostate
Number of subjects: 109
Study: 17880352

Group type: EXPERIMENTAL
Intervention: 12-step involvement
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Spirituality measures (Religious Background and Behaviors scale and spiritual awakening item)
Number of subjects: 733
Study: 15083783

Group type: EXPERIMENTAL
Intervention: 3-cm surgical excision margin
Number of subjects: 426

Group type: COMPARATOR
Intervention: 1-cm surgical excision margin
Number of subjects: 426
Study: 12516995

Group type: EXPERIMENTAL
Intervention: Meningococcal C conjugate vaccine
Number of subjects: 351

Group type: COMPARATOR
Intervention: Control (Hepatitis B vaccine)
Number of subjects: 351
Study: 9658375

Group type: EXPERIMENTAL
Intervention: Combined hepatitis A/hepatitis B vaccine (3 injections at 0, 1, and 6 months)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Combined hepatitis A/hepatitis B vaccine
Number of subjects: 242
Study: 8017413

Group type: EXPERIMENTAL
Intervention: 300 mg immediate-release lithium carbonate tablets (Lithotab)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 450 mg extended-release lithium carbonate tablets (Eskalith CR)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 300 mg extended-release lithium carbonate tablets (Lithobid)
Number of subjects: 12

Group type: COMPARATOR
Intervention: All three products
Number of subjects: 12
Study: 2688618

Group type: EXPERIMENTAL
Intervention: 1% apraclonidine hydrochloride
Number of subjects: 10

Group type: COMPARATOR
Intervention: Contralateral eye (control)
Number of subjects: 10
Study: 162924

Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside (3 mg/kg every 24 hr for up to 7 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside
Number of subjects: 20
Study: 31562018

Group type: EXPERIMENTAL
Intervention: 2D-generated wall structure
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 3D-generated wall structure
Number of subjects: 10
Study: 31397727

Group type: EXPERIMENTAL
Intervention: Intensive counselling with trained disclosure counsellors and culturally tailored materials
Number of subjects: 285

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 285
Study: 27913092

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No stimulation
Number of subjects: 8
Study: 26698241

Group type: EXPERIMENTAL
Intervention: PLIF operation group
Number of subjects: 66

Group type: COMPARATOR
Intervention: Wallis operation group
Number of subjects: 66
Study: 23411886

Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant
Number of subjects: 224
Study: 21195296

Group type: EXPERIMENTAL
Intervention: Verum acupuncture (VA)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 14
Study: 19446144

Group type: EXPERIMENTAL
Intervention: Lidocaine patch applied to the trigger point for 4 days (total daily dose, 350 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Infiltration of the trigger point with two 1-mL injections of 0.5% bupivacaine hydrochloride given 2 days apart
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo patch applied to the trigger point for 4 days
Number of subjects: 60
Study: 17308963

Group type: EXPERIMENTAL
Intervention: Reviparin (Clivarin) 3,436 IU anti-Xa/0.6 ml, self-administered twice daily for 8 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 15111849

Group type: EXPERIMENTAL
Intervention: Dacron patch (Hemashield Finesse) closure
Number of subjects: 273

Group type: COMPARATOR
Intervention: Vein closure
Number of subjects: 273
Study: 10389549

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 200 micrograms
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study: 8779367

Group type: EXPERIMENTAL
Intervention: Isoflurane 1.0 MAC
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nitrous oxide in oxygen (2:1) anaesthesia supplemented with fentanyl
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isoflurane 0.25 MAC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isoflurane 0.5 MAC
Number of subjects: 60
Study: 1739321

Group type: EXPERIMENTAL
Intervention: Intensive individual speech therapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Weekly speech therapy
Number of subjects: 42
Study: 6473024

Group type: EXPERIMENTAL
Intervention: Marijuana
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Imagery instructions
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 30856542

Group type: EXPERIMENTAL
Intervention: Project Dulce diabetes care management (PD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Project Dulce with technology enhancement (PD-TE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0
Study: 30142818

Group type: EXPERIMENTAL
Intervention: Acupotomy
Number of subjects: 146

Group type: COMPARATOR
Intervention: Manual acupuncture
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 146
Study: 27514456

Group type: EXPERIMENTAL
Intervention: New suturing technique
Number of subjects: 128

Group type: COMPARATOR
Intervention: Traditional suturing technique
Number of subjects: 128